Munich Lung Transplant Group: Waiting List during the First 9 Months of the Lung Allocation Score Era

Abstract

Objective and Methods The Eurotransplant Foundation introduced the lung allocation score (LAS) in Germany on December 10, 2011. We analyzed characteristics of the Munich Lung Transplant Group (MLTG) waiting list during the first 9 months after the introduction of the LAS.

Results A mean number of 39 ± 1 patients were constantly listed for lung transplantation and 60 transplants were performed by the MLTG during the observation period. While the majority (42 ± 0%) of patients waiting for transplant comprised chronic obstructive pulmonary disease (COPD)/emphysema patients, only 26% of transplanted patients suffered from COPD/emphysema. Instead, the majority (42%) of transplanted patients suffered from interstitial lung disease. Waiting times did not markedly change in the LAS era. Notably, patients with interstitial lung disease had shorter waiting times when compared with patients suffering from COPD/emphysema and cystic fibrosis, both on the waiting list and at the time of transplant.

Conclusion The MLTG lung transplant waiting list has not markedly changed during the first 9 months after the introduction of the LAS. Our data indicate that the LAS accommodates disease-specific patient statuses well. Although patients with interstitial lung disease are preferably transplanted, the LAS system provides a very reasonable basis to also list and transplant COPD/emphysema patients.

Keywords

lung transplantation - lung allocation score - waiting list

• References

• 1 Smits JM, Nossent GD, de Vries E , et al. Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant. J Heart Lung Transplant 2011; 30 (1) 22-28
• 2 Colvin-Adams M, Valapour M, Hertz M , et al. Lung and heart allocation in the United States. Am J Transplant 2012; 12 (12) 3213-3234
• 3 Egan TM, Murray S, Bustami RT , et al. Development of the new lung allocation system in the United States. Am J Transplant 2006; 6 (5, Pt 2) 1212-1227
• 4 Carbone R, Balleari E, Grosso M, Montanaro F, Bottino G, Ghio R. Predictors of mortality of idiopathic pulmonary fibrosis. Eur Rev Med Pharmacol Sci 2008; 12 (2) 97-104
• 5 Kimura M, Taniguchi H, Kondoh Y , et al. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 2013; 85 (6) 456-463
• 6 Kim JH, Lee JH, Ryu YJ, Chang JH. Clinical predictors of survival in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul) 2012; 73 (3) 162-168
• 7 Metzger NL, Lundquist LM. A review of the advances in chronic obstructive pulmonary disease treatment. J Pharm Pract 2012; 25 (6) 576-582
• 8 Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28 (6) 1245-1257
• 9 Shigemura N, Bermudez C, Hattler BG , et al. Impact of graft volume reduction for oversized grafts after lung transplantation on outcome in recipients with end-stage restrictive pulmonary diseases. J Heart Lung Transplant 2009; 28 (2) 130-134
• 10 Neurohr C, Huppmann P, Thum D , et al; Munich Lung Transplant Group. Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int 2010; 23 (9) 887-896
• 11 Wang Q, Rogers CA, Bonser RS, Banner NR, Demiris N, Sharples LD. UK Cardiothoracic Transplant Steering Group. Assessing the benefit of accepting a single lung offer now compared with waiting for a subsequent double lung offer. Transplantation 2011; 91 (8) 921-926
• 12 Mason DP, Rajeswaran J, Murthy SC , et al. Spirometry after transplantation: how much better are two lungs than one?. Ann Thorac Surg 2008; 85 (4) 1193-1201 , e1–e2
• 13 Rinaldi M, Sansone F, Boffini M , et al. Single versus double lung transplantation in pulmonary fibrosis: a debated topic. Transplant Proc 2008; 40 (6) 2010-2012